• Comment

    US proposal a 'game over' moment for Australian access

    The obvious and inevitable risk of the proposal is that companies will act to innoculate their larger and more lucrative market by not launching or significantly delaying the launch of new medicines in Australia. They may even be forced to consider removing already reimbursed medicines.